Avalo Therapeutics, Inc. Common Stock
AVTXAvalo Therapeutics, Inc. (AVTX) is a biotechnology company focused on developing innovative therapies for immune-inflammatory and specialized conditions. The company leverages its expertise in immunology and inflammation to advance treatments aimed at improving patient outcomes in chronic and rare diseases.
Company News
Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β pathway therapeutics, announced its inclusion in the Russell 2000 and Russell 3000 indexes effective June 26, 2026. The company's lead asset abdakibart, an anti-IL-1β monoclonal antibody, recently reported positive Phase 2 data in hidradenitis suppurativa, with plans to advan...
Avalo Therapeutics priced an underwritten public offering of 19.73 million shares at $17.75 per share and 1.4 million pre-funded warrants, expected to raise approximately $375 million in gross proceeds. The company plans to use the funds to advance clinical development of its lead asset abdakibart, including Phase 3 topline data release, followin...
Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, announced that management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conferenc...
A comprehensive analysis reveals a robust pipeline for hidradenitis suppurativa treatment, with 24+ companies developing 26+ therapies, focusing on innovative biologic and targeted approaches like IL-17 and JAK inhibitors to address significant unmet clinical needs.
Merus NV shares jumped 38.2% in pre-market trading after Genmab announced plans to acquire the company for $8 billion in an all-cash deal, adding breakthrough therapy Petosemtamab to its late-stage pipeline.
